Literature DB >> 26279576

Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.

Behnam Nabet1, Pilib Ó Broin2, Jaime M Reyes3, Kevin Shieh2, Charles Y Lin3, Christine M Will4, Relja Popovic4, Teresa Ezponda4, James E Bradner3, Aaron A Golden5, Jonathan D Licht6.   

Abstract

Unrestrained receptor tyrosine kinase (RTK) signaling and epigenetic deregulation are root causes of tumorigenesis. We establish linkage between these processes by demonstrating that aberrant RTK signaling unleashed by oncogenic HRas(G12V) or loss of negative feedback through Sprouty gene deletion remodels histone modifications associated with active typical and super-enhancers. However, although both lesions disrupt the Ras-Erk axis, the expression programs, enhancer signatures, and transcription factor networks modulated upon HRas(G12V) transformation or Sprouty deletion are largely distinct. Oncogenic HRas(G12V) elevates histone 3 lysine 27 acetylation (H3K27ac) levels at enhancers near the transcription factor Gata4 and the kinase Prkcb, as well as their expression levels. We show that Gata4 is necessary for the aberrant gene expression and H3K27ac marking at enhancers, and Prkcb is required for the oncogenic effects of HRas(G12V)-driven cells. Taken together, our findings demonstrate that dynamic reprogramming of the cellular enhancer landscape is a major effect of oncogenic RTK signaling.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26279576      PMCID: PMC4551578          DOI: 10.1016/j.celrep.2015.06.078

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  46 in total

1.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4.

Authors:  Lisa Ann Cirillo; Frank Robert Lin; Isabel Cuesta; Dara Friedman; Michal Jarnik; Kenneth S Zaret
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

2.  MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14.

Authors:  Ana Soloaga; Stuart Thomson; Giselle R Wiggin; Navita Rampersaud; Mark H Dyson; Catherine A Hazzalin; Louis C Mahadevan; J Simon C Arthur
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

3.  sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways.

Authors:  N Hacohen; S Kramer; D Sutherland; Y Hiromi; M A Krasnow
Journal:  Cell       Date:  1998-01-23       Impact factor: 41.582

4.  Latent enhancers activated by stimulation in differentiated cells.

Authors:  Renato Ostuni; Viviana Piccolo; Iros Barozzi; Sara Polletti; Alberto Termanini; Silvia Bonifacio; Alessia Curina; Elena Prosperini; Serena Ghisletti; Gioacchino Natoli
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

5.  Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling.

Authors:  Katherine Shim; George Minowada; Donald E Coling; Gail R Martin
Journal:  Dev Cell       Date:  2005-04       Impact factor: 12.270

6.  (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.

Authors:  M R Jirousek; J R Gillig; C M Gonzalez; W F Heath; J H McDonald; D A Neel; C J Rito; U Singh; L E Stramm; A Melikian-Badalian; M Baevsky; L M Ballas; S E Hall; L L Winneroski; M M Faul
Journal:  J Med Chem       Date:  1996-07-05       Impact factor: 7.446

7.  The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes.

Authors:  Q Liang; R J Wiese; O F Bueno; Y S Dai; B E Markham; J D Molkentin
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction.

Authors:  M Albert Basson; Simge Akbulut; Judy Watson-Johnson; Ruth Simon; Thomas J Carroll; Reena Shakya; Isabelle Gross; Gail R Martin; Thomas Lufkin; Andrew P McMahon; Patricia D Wilson; Frank D Costantini; Ivor J Mason; Jonathan D Licht
Journal:  Dev Cell       Date:  2005-02       Impact factor: 12.270

9.  GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5.

Authors:  Vidu Garg; Irfan S Kathiriya; Robert Barnes; Marie K Schluterman; Isabelle N King; Cheryl A Butler; Caryn R Rothrock; Reenu S Eapen; Kayoko Hirayama-Yamada; Kunitaka Joo; Rumiko Matsuoka; Jonathan C Cohen; Deepak Srivastava
Journal:  Nature       Date:  2003-07-06       Impact factor: 49.962

10.  c-Ha-rasVal 12 oncogene-transformed NIH-3T3 fibroblasts display more decondensed nucleosomal organization than normal fibroblasts.

Authors:  J Laitinen; L Sistonen; K Alitalo; E Hölttä
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

View more
  24 in total

Review 1.  Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

Authors:  Satyaki Sengupta; Rani E George
Journal:  Trends Cancer       Date:  2017-04-12

2.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Authors:  Jon S Zawistowski; Samantha M Bevill; Daniel R Goulet; Timothy J Stuhlmiller; Adriana S Beltran; Jose F Olivares-Quintero; Darshan Singh; Noah Sciaky; Joel S Parker; Naim U Rashid; Xin Chen; James S Duncan; Martin C Whittle; Steven P Angus; Sara Hanna Velarde; Brian T Golitz; Xiaping He; Charlene Santos; David B Darr; Kristalyn Gallagher; Lee M Graves; Charles M Perou; Lisa A Carey; H Shelton Earp; Gary L Johnson
Journal:  Cancer Discov       Date:  2017-01-20       Impact factor: 39.397

3.  Landscaping a chromatin response to MEK inhibition.

Authors:  Jon S Zawistowski; Daniel R Goulet; Gary L Johnson
Journal:  Cell Cycle       Date:  2017-03-13       Impact factor: 4.534

Review 4.  Transcriptional Addiction in Cancer.

Authors:  James E Bradner; Denes Hnisz; Richard A Young
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 5.  Chromatin dependencies in cancer and inflammation.

Authors:  Ivan Marazzi; Benjamin D Greenbaum; Diana H P Low; Ernesto Guccione
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-29       Impact factor: 94.444

6.  MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.

Authors:  Marielle E Yohe; Berkley E Gryder; Jack F Shern; Young K Song; Hsien-Chao Chou; Sivasish Sindiri; Arnulfo Mendoza; Rajesh Patidar; Xiaohu Zhang; Rajarashi Guha; Donna Butcher; Kristine A Isanogle; Christina M Robinson; Xiaoling Luo; Jin-Qiu Chen; Ashley Walton; Parirokh Awasthi; Elijah F Edmondson; Simone Difilippantonio; Jun S Wei; Keji Zhao; Marc Ferrer; Craig J Thomas; Javed Khan
Journal:  Sci Transl Med       Date:  2018-07-04       Impact factor: 17.956

7.  The dTAG system for immediate and target-specific protein degradation.

Authors:  Behnam Nabet; Justin M Roberts; Dennis L Buckley; Joshiawa Paulk; Shiva Dastjerdi; Annan Yang; Alan L Leggett; Michael A Erb; Matthew A Lawlor; Amanda Souza; Thomas G Scott; Sarah Vittori; Jennifer A Perry; Jun Qi; Georg E Winter; Kwok-Kin Wong; Nathanael S Gray; James E Bradner
Journal:  Nat Chem Biol       Date:  2018-03-26       Impact factor: 15.040

Review 8.  Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity.

Authors:  Luca Fagnocchi; Vittoria Poli; Alessio Zippo
Journal:  Cell Mol Life Sci       Date:  2018-04-24       Impact factor: 9.261

Review 9.  Enhancer rewiring in tumors: an opportunity for therapeutic intervention.

Authors:  Laia Richart; François-Clément Bidard; Raphaël Margueron
Journal:  Oncogene       Date:  2021-05-01       Impact factor: 9.867

10.  Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.

Authors:  Peng Zhang; Fuhong He; Jie Bai; Shohei Yamamoto; Shi Chen; Lin Zhang; Mengyao Sheng; Lei Zhang; Ying Guo; Na Man; Hui Yang; Suyun Wang; Tao Cheng; Stephen D Nimer; Yuan Zhou; Mingjiang Xu; Qian-Fei Wang; Feng-Chun Yang
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.